AC

Acarix ABFNSE Acarix Stock Report

Last reporting period 30 Jun, 2024

Updated 21 Oct, 2024

Last price

Market cap $B

0.029

Micro

Exchange

FNSE - First North Sweden

ACARIX.ST Stock Analysis

AC

Uncovered

Acarix AB is uncovered by Eyestock quantitative analysis.

Rating

To assess the quality of a company's business, we have collected all financial data from the statements and presented them in the form of a single number - the company's rating. Rating value of 100 is the threshold for determining a viable investment.

9/100

Low score

Market cap $B

0.029

Dividend yield

Shares outstanding

373.33 B

Acarix AB is engaged in the provision of medical devices for monitoring Coronary Artery Disease. The company is headquartered in Malmo, Skane. The company went IPO on 2016-12-19. The Company’s primary product CADScor System features phonocardiography technique and algorithms. The CADScor System is fixed with a specific patch to the chest of the patient, with the recording head placed at the forth left intercostal space, and the sensor resting on the sternum. Instructions for the procedure are given on the display for the operator and audio cues guide a patient during the two-minute heart sound recording. After recording, the CAD-score is calculated, and presented on the display of the CADScor Sensor, enabling a physicians, nurses and laboratory technicians to make a rule-out diagnosis.

View Section: Eyestock Rating